Skip to content
10-Q

Quarterly Report

Lakewood-Amedex Biotherapeutics Inc. LABT

0001213900-26-060640

← back to feed
Filed
May 22, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 7M sh
Shares Diluted Q1 2026 · Mar 31, 2025 6.94M sh
Shares Outstanding Q1 2026 · Mar 31, 2026 7M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$349.69K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$404.09K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $11.71K
Cash And Equivalents Q1 2026 · Dec 31, 2025 $236.4K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$2.84M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$1.96M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$76.23K
Stockholders Equity Q1 2026 · Dec 31, 2024 $409.61K
Current Liabilities Q1 2026 · Mar 31, 2026 $3.03M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.41M
Total Liabilities Q1 2026 · Mar 31, 2026 $3.04M
Total Liabilities Q1 2026 · Dec 31, 2025 $2.45M
Current Assets Q1 2026 · Mar 31, 2026 $50.63K
Current Assets Q1 2026 · Dec 31, 2025 $305.39K
Total Assets Q1 2026 · Mar 31, 2026 $196.34K
Total Assets Q1 2026 · Dec 31, 2025 $481.6K
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.20
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.15
Eps Basic Q1 2026 · Mar 31, 2026 −$0.20
Eps Basic Q1 2026 · Mar 31, 2025 −$0.15
Sga Expense Q1 2026 · Mar 31, 2026 $703.44K
Sga Expense Q1 2026 · Mar 31, 2025 $371.75K
Rd Expense Q1 2026 · Mar 31, 2026 $182.15K
Rd Expense Q1 2026 · Mar 31, 2025 $169.7K
Net Income Q1 2026 · Mar 31, 2026 −$923.29K
Net Income Q1 2026 · Mar 31, 2025 −$539.62K
Operating Income Q1 2026 · Mar 31, 2026 −$886.75K
Operating Income Q1 2026 · Mar 31, 2025 −$542.61K
Cost Of Revenue Q1 2026 · Mar 31, 2026 $507.29K